Exposure to air pollutants, such as fine particulate matter and nitrogen dioxide, may increase the risk of developing Parkinson’s disease and dyskinesia, or involuntary movements, according to a study using data from the Rochester Epidemiology Project. These findings add to growing evidence that breathing polluted air is a…
GT-02287, a potential therapy for Parkinson’s disease, showed promising results in a Phase 1 clinical trial involving healthy volunteers, according to data announced by developer Gain Therapeutics. The investigational treatment was found to be safe and well tolerated at doses projected to be effective in people with the neurodegenerative…
Note: This story was updated Oct. 7, 2024, to correct references to the open-label extension study of the BounDNless trial. A year of treatment with ND0612, an investigational liquid formulation of levodopa/carbidopa continuously administered as an infusion under the skin, sustainably reduced the periods of time when motor symptoms…
A neural platform based on graphene, a strong but extremely thin carbon sheet that Inbrain Neuroelectronics is developing for a surgical treatment of Parkinson’s disease, was used for a first time on a patient undergoing brain tumor surgery. The platform’s graphene-based brain-computer interface (BCI) technology demonstrated an ability…
Genetic variants found in the DNA of mitochondria, the cell compartments that produce energy, were associated with the severity of Gulf War Illness (GWI), a chronic condition seen in Gulf War veterans that’s associated with environmental toxin exposure, a study found. The research team, led by scientists at the…
Patients treated with bemdaneprocel, a cell therapy that Bluerock Therapeutics is developing for Parkinson’s disease, continue to spend more time with well-controlled symptoms and less time in off periods, when symptoms aren’t adequately controlled despite medication use. That’s according to final data from exPDite (NCT04802733), a completed…
Reasonable safety is being seen in a first group of Parkinson’s disease patients who finished dosing in a Phase 1/2a clinical trial of ANPD001, Aspen Neurosciences’ investigational stem cell therapy aiming to replace the nerve cells lost to the disease. The three treated adults were given two…
A compound called IU1 may improve the body’s ability to maintain healthy proteins by boosting two critical processes that play a role in removing damaged proteins from cells, a study shows. The findings could have implications for age-related conditions like Parkinson’s disease. The study, “Pharmacological inhibition of…
Treatment with tavapadon as a fixed-dose single therapy significantly improved motor function in early stage Parkinson’s disease, according to top-line data from a completed Phase 3 trial. Full results from TEMPO-1 (NCT04201093) will be presented at future medical meetings and support regulatory submissions toward the investigational therapy’s approval.
A mutation in the RAB32 gene, which has been previously associated with Parkinson’s disease, was found in a significant number of individuals participating in an international study. Specifically, researchers found this mutation more than 100 times more prevalent in Parkinson’s patients than in the general population. These data came…
Get regular updates to your inbox.
